<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01663415</url>
  </required_header>
  <id_info>
    <org_study_id>9785-UC-0001</org_study_id>
    <nct_id>NCT01663415</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate radiographic progression-free survival (PFS) of
      enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant
      prostate cancer who have symptomatic disease.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    A business decision was made to not initiate this study.
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic progression free survival (PFS)</measure>
    <time_frame>26 months</time_frame>
    <description>Time from first dose on Day 1 to the first objective evidence of radiographic progression or death due to any cause (whichever occurs first). Radiographic disease progression is defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Prostate Cancer Clinical Trials Working Group 2 (PCWG2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>26 months</time_frame>
    <description>Time from first dose on Day 1 to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>26 months</time_frame>
    <description>Time from first dose on Day 1 to first observation of PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to last post baseline measurement Quality of life score using Functional Assessment of Cancer Therapy-Prostate (FACT-P)</measure>
    <time_frame>Baseline and 26 months</time_frame>
    <description>The FACT-P quality of life questionnaire is a multi-dimensional, self-reported quality of life instrument specifically designed for use with prostate cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to last post baseline measurement Quality of Life score using European Quality of Life 5-Domain Scale (EQ-5D)</measure>
    <time_frame>Baseline and 26 months</time_frame>
    <description>EQ-5D is a standardized instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status and is designed for self-completion by respondents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to last post baseline measurement Pain Assessments (Brief Pain Inventory - Short Form)</measure>
    <time_frame>Baseline and 26 months</time_frame>
    <description>Brief Pain Inventory is a validated instrument that is a subject self-rating scale assessing level of pain, effect of the pain on activities of daily living, and analgesic use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording of adverse events, safety laboratory evaluations, vital signs and electrocardiograms (ECGs)</measure>
    <time_frame>26 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>oral</description>
    <arm_group_label>Enzalutamide</arm_group_label>
    <other_name>MDV3100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Progressive prostate cancer while on androgen deprivation therapy

          -  Castrate testosterone level

          -  Maintenance of surgical or medical castration for duration of study

          -  Radiographically visible metastatic disease

          -  Symptomatic from prostate cancer

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Life expectancy &gt;=6 months

        Exclusion Criteria:

          -  Brain metastases or leptomeningeal disease

          -  Prior cytotoxic chemotherapy for prostate cancer

          -  Prior use of ketoconazole or abiraterone acetate or other investigational agent that
             blocks androgen synthesis or targets androgen receptor

          -  History of seizure or condition that may predispose to seizure

          -  History of loss of consciousness or transient ischemic attack within 12 months

          -  Clinically significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2012</study_first_submitted>
  <study_first_submitted_qc>August 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2012</study_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDV3100</keyword>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>enzalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

